Millenium Pharma to Evaluate Horizon Discovery's Human and Mutant Cell Lines | GenomeWeb
NEW YORK (GenomeWeb News) – Horizon Discovery said today that Millenium Pharmaceuticals will evaluate seven of Horizon’s X-MAN normal and mutant isogenic cell lines during an eight-month period.
 
The X-MAN cell lines may help speed the discovery of personalized cancer medicine, the company said. These cell lines are genetically defined in vitro models of human cancer and their matched normal cell types. They include a set of double cancer-gene "knock-in" lines designed to evaluate patient resistance to targeted agents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.